نتائج البحث

Icotinib for Completed Resected IB NSCLC With EGFR Mutation (CORIN)

• Authors : Si-Yu Wang, Professor

• Source: A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor

تفاصيل العنوان

Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation (ICTAN)

• Authors : Si-Yu Wang, Professor

• Source: A Multicenter, Randomized, Phase III Trial of Chemotherapy Followed by 6-month or 12-month Icotinib Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA Non-small

تفاصيل العنوان

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

• Source: A Phase II/III, Open-Label, Randomised Study to Assess the Safety and Efficacy of D-0316 Versus Icotinib as First Line Treatment in Patients With EGFR Sensitising

تفاصيل العنوان

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

• Authors : The First Affiliated Hospital of Xiamen University

• Source: A Phase II, Single Arm, Study to Assess Befotertinib and Icotinib as First-Line Treatment in Patients With Locally Advanced or Metastatic NSCLC and Sensitising EGFR

تفاصيل العنوان

Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result.

• Authors : Hong, Yaping^1,2 (AUTHOR); Zhuang, Wu^1,2 (AUTHOR); Lai, Jinhuo³ (AUTHOR)

• Source: Scientific Reports. 10/4/2024, Vol. 14 Issue 1, p1-13. 13p.

تفاصيل العنوان

Acute generalized exanthematous pustulosis induced by icotinib: a case report and literature review

• Authors : Wei Yang; Jiayu Zhao; Jun Niu

Subjects: non-small cell lung cancer; tyrosine kinase inhibitor; icotinib

• Source: Frontiers in Pharmacology, Vol 15 (2024)

تفاصيل العنوان

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations (IcomBine)

• Authors : Xue Hou, Principal Investigator

• Source: A Phase II Study to Assess Befotertinib and Icotinib as First-Line Treatment in Patients With Locally Advanced or Metastatic NSCLC and Uncommon EGFR Mutation(IcomBine,

تفاصيل العنوان

Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result

• Authors : Yaping Hong; Wu Zhuang; Jinhuo Lai

Subjects: Non-small cell lung cancer; Epidermal growth factor receptor; Circulating tumor DNA

• Source: Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)

تفاصيل العنوان

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study

• Authors : Linlin Zhang; Liuchun Wang; Jingya Wang

Subjects: Non-small-cell lung cancer; ErbB receptors; Prognosis

• Source: Molecular Cancer, Vol 22, Iss 1, Pp 1-11 (2023)

تفاصيل العنوان

Case report: Efficacy of icotinib treatment in lung adenocarcinoma with esophageal squamous cell carcinoma: a rare case of double primary malignant tumors

• Authors : Min Deng; Xiaoqing Li; Honghao Mu

Subjects: lung adenocarcinoma; esophageal squamous cell carcinoma; double primary malignant tumors

• Source: Frontiers in Medicine, Vol 11 (2024)

تفاصيل العنوان